Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
496.66M | 160.10M | 7.60M | 5.21M | 3.48M | Gross Profit |
308.50M | 29.34M | -29.77M | -16.88M | -11.88M | EBIT |
51.89M | -73.18M | -81.25M | -49.25M | -40.26M | EBITDA |
22.97M | -92.84M | -70.07M | -44.94M | -36.17M | Net Income Common Stockholders |
5.21M | -104.08M | -80.51M | -44.89M | -27.87M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
123.24M | 116.33M | 22.04M | 77.94M | 44.60M | Total Assets |
398.30M | 260.59M | 109.81M | 164.44M | 102.61M | Total Debt |
17.45M | 10.45M | 2.54M | 2.21M | 2.13M | Net Debt |
-105.79M | -105.88M | -19.50M | -75.74M | -42.47M | Total Liabilities |
249.39M | 178.44M | 106.17M | 84.44M | 31.88M | Stockholders Equity |
148.91M | 80.01M | 2.16M | 79.02M | 70.08M |
Cash Flow | Free Cash Flow | |||
13.09M | -77.83M | -60.67M | 1.64M | -23.80M | Operating Cash Flow |
23.88M | -63.97M | -59.33M | 1.96M | -23.33M | Investing Cash Flow |
-25.49M | -17.00M | -2.73M | -1.09M | -468.00K | Financing Cash Flow |
10.19M | 174.96M | 2.85M | 34.12M | 42.72M |
Telix Pharmaceuticals Limited has issued 91,168 fully paid ordinary shares following the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business. This move, executed without disclosure under Part 6D.2 of the Corporations Act, signifies Telix’s strategic expansion in the radio-guided surgery market, potentially enhancing its industry positioning and stakeholder value.
Telix Pharmaceuticals Limited has announced the quotation of 91,168 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 6, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve its market position, offering stakeholders an opportunity to engage with the company’s growth and development in the biotech sector.
Telix Pharmaceuticals announced the resignation of Anne Whitaker from its board due to personal and family reasons, effective immediately. This resignation impacts the upcoming Annual General Meeting as her nomination for election has been withdrawn, but it does not affect the validity of proxy forms for the meeting. The company expressed regret over her departure and extended best wishes for her future endeavors.
Telix Pharmaceuticals Limited has announced the release of 2,427,636 ordinary shares from voluntary escrow, which were initially issued to QSAM Biosciences Inc. shareholders as part of Telix’s acquisition of QSAM. This release, scheduled for May 3, 2025, is in accordance with ASX Listing Rule 3.10A and marks a significant step in the integration process following the acquisition. The release of these shares is expected to impact Telix’s market operations by potentially increasing the liquidity of its shares and enhancing shareholder value.
Telix Pharmaceuticals Ltd. reported a significant 62% year-over-year increase in Q1 2025 revenue, reaching $186 million, driven by strong sales of Illuccix® and contributions from the recent acquisition of RLS Radiopharmacies. The company reaffirmed its FY 2025 revenue guidance and highlighted strategic expansions, including new market approvals and acquisitions, which are expected to enhance its global footprint and product offerings. The launch of Gozellix® in the U.S. and advancements in its therapeutic pipeline, such as the development of a new generator technology for lead-212, underscore Telix’s commitment to innovation and growth in the radiopharmaceutical sector.
Telix Pharmaceuticals Limited has announced promising preliminary results from the Phase 2 IPAX-Linz study of TLX101, a glioma therapy candidate, in patients with recurrent high-grade glioma. The study showed that TLX101, in combination with external beam radiation therapy, was well tolerated and demonstrated encouraging efficacy, with a median overall survival of 12.4 months from treatment initiation. These findings suggest TLX101’s potential to improve outcomes for patients with high-grade glioma, supporting further research and higher therapeutic doses in future studies.
Telix Pharmaceuticals Limited has announced a change in the address of its registry office in Sydney, which is now located at Liberty Place, Level 41, 161 Castlereagh St, Sydney NSW 2000. This relocation is part of the company’s ongoing operational adjustments, reflecting its commitment to maintaining efficient administrative processes and potentially impacting its stakeholder communications.
Telix Pharmaceuticals Limited has announced that the recent U.S. government trade tariffs will not materially impact its business or supply chain. This is due to its extensive U.S.-based manufacturing and distribution infrastructure and the exemption of pharmaceutical products from these tariffs. Additionally, Telix is unaffected by Chinese export controls on rare earth elements, as these are not used in its products. The company remains on track with its new drug applications, despite changes at the FDA, and plans to continue its ‘just-in-time’ production approach for radiopharmaceuticals.
Telix Pharmaceuticals Limited has announced the release of 9,684 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Dedicaid GmbH. This release, scheduled for April 16, 2025, is in accordance with ASX Listing Rule 3.10A and reflects Telix’s ongoing strategic efforts to integrate acquisitions and enhance its market presence.
Telix Pharmaceuticals Limited announced the release of 237,669 ordinary shares from voluntary escrow, which were initially issued to the vendors of ARTMS Inc. as part of its acquisition. This release, scheduled for April 11, 2025, marks a significant step in integrating ARTMS into Telix’s operations, potentially enhancing its market positioning and offering new opportunities for stakeholders.
Telix Pharmaceuticals Ltd. has announced a change in the substantial holding of its voting securities, with State Street Bank and Trust Company and its subsidiaries being key players in this change. This adjustment in voting power could influence the company’s governance and strategic decisions, potentially impacting its market position and stakeholder interests.
Telix Pharmaceuticals Limited announced the release of 717,587 ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of IsoTherapeutics Group, LLC. This release, scheduled for 9 April 2025, reflects a strategic move following the acquisition, potentially impacting the company’s market dynamics and stakeholder interests.
Telix Pharmaceuticals has received approval from Brazil’s ANVISA for its prostate cancer imaging agent, Illuccix®, marking its first marketing authorization in Latin America. This approval, in partnership with R2PHARMA, allows Telix to expand its presence in the rapidly growing Brazilian radiopharmaceutical market, addressing the significant demand for advanced cancer imaging solutions. The joint venture with R2PHARMA aims to further commercialize Telix’s products in Brazil, leveraging local expertise to enhance access to innovative diagnostic and therapeutic radiopharmaceuticals.
Telix Pharmaceuticals Ltd. has issued 13,356 fully paid ordinary shares as part of an earn-out consideration following the regulatory approval of a clinical decision support software AI platform. This issuance is linked to the acquisition of Dedicaid GmbH, reflecting Telix’s strategic efforts to integrate advanced technologies and expand its capabilities in clinical decision support, thereby strengthening its industry positioning.
Telix Pharmaceuticals Ltd. announced the cessation of certain securities, specifically 11,000 share rights and 263,001 share appreciation rights, due to unmet conditions. This development may impact the company’s financial structuring and investor relations, as these securities were unable to meet the necessary conditions for continuation.
Telix Pharmaceuticals Ltd. has announced a change in the director’s interest notice, specifically involving Dr. Christian Behrenbruch. The change involves the disposal of 46,558 Performance Share Appreciation Rights, reducing the total held by Dr. Behrenbruch. This update reflects ongoing adjustments in the company’s executive shareholding structure, which may impact stakeholder perceptions and the company’s market positioning.
Telix Pharmaceuticals Limited has completed the acquisition of FAP-targeting theranostic candidates, expanding its pipeline with new compounds aimed at Fibroblast Activation Protein, a promising target in nuclear medicine for cancer treatment. This strategic acquisition enhances Telix’s urology focus and pan-cancer therapeutic potential, positioning the company to deliver innovative theranostic solutions and strengthen its market presence in oncology.
Telix Pharmaceuticals Ltd. has announced a change in the director’s interest, specifically involving Harry Kevin McCann, who has disposed of 30,000 fully paid ordinary shares at $30.43 per share. This transaction reflects a minor adjustment in the director’s holdings, with implications for the company’s governance and shareholder structure, although it does not significantly impact the company’s overall market position or operations.
Telix Pharmaceuticals Limited is hosting an investor webinar to showcase its late-stage and next-generation radiotherapeutic candidates in urologic oncology, focusing on prostate and kidney cancers. The event will feature discussions by prominent medical professionals on Telix’s leading radio antibody-drug conjugate therapy candidates, including TLX591 for prostate cancer and TLX250 in combination with immunotherapy for renal cell carcinoma. This initiative underscores Telix’s commitment to advancing its oncology pipeline and highlights its strategic positioning in the biopharmaceutical industry.
Telix Pharmaceuticals Ltd. has announced a change in the indirect interest of its director, Dr. Christian Behrenbruch, who disposed of 2,000,000 fully paid ordinary shares held by Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust. This transaction, valued at $29.50 per share, reduces the indirect interest to 20,675,000 shares, potentially impacting the company’s market perception and stakeholder confidence.
Telix Pharmaceuticals Limited announced the completion of a significant share sale by its CEO, Dr. Christian Behrenbruch, and co-founder Dr. Andreas Kluge, each selling 2,000,000 shares at $29.50 per share through block trades. Both executives have agreed to a twelve-month lock-up on their remaining shares, indicating no immediate plans for further sales. This transaction reflects strategic financial management within the company, potentially impacting investor perceptions and market dynamics.
Telix Pharmaceuticals announced that its CEO, Dr. Christian Behrenbruch, plans to sell 2,000,000 shares, representing less than 10% of his holdings, for personal reasons related to a divorce settlement and estate planning. The sale, approved by the Board, will occur after the company’s annual financial results release, and Dr. Behrenbruch has committed to a twelve-month lock-up period prohibiting further sales. This move is not expected to impact his commitment to the company, as he remains a major shareholder with approximately 6.30% of Telix’s issued capital.
Telix Pharmaceuticals Limited announced that the FDA has accepted the Biologics License Application for TLX250-CDx, a novel imaging agent for kidney cancer, granting it a Priority Review. This development positions Telix to potentially launch the first imaging agent capable of accurately diagnosing clear cell renal cell carcinoma, enhancing the company’s standing in precision medicine and potentially transforming kidney cancer management.
Telix Pharmaceuticals Limited has announced significant changes to its Board of Directors as part of a succession planning and renewal process. H Kevin McCann AO will retire as Non-Executive Director and Board Chairman, with Tiffany Olson set to succeed him. Additionally, Marie McDonald will join the Board as a Non-Executive Director and Chair of the People Committee. These changes aim to support Telix’s growth trajectory, global expansion, and recent Nasdaq dual-listing, enhancing the diversity and expertise within the Board.
Telix Pharmaceuticals Limited announced a change in its reporting currency from Australian dollars to United States dollars, effective January 1, 2025. This shift aligns with the company’s revenue, costs, and cash flows predominantly generated in the U.S., potentially streamlining financial reporting and enhancing clarity for stakeholders.
Telix Pharmaceuticals Ltd. has released its latest corporate governance statement in compliance with ASX Listing Rules. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council Principles and Recommendations for the financial year ending December 31, 2024. This move reinforces Telix’s commitment to transparency and accountability, potentially strengthening its position in the market and assuring stakeholders of its robust governance practices.
Telix Pharmaceuticals Ltd. has announced its full year results for FY2024, highlighting the approval and market presence of its lead imaging product, Illuccix®, across multiple jurisdictions, including the U.S., Australia, and Canada. The company’s osteomyelitis imaging agent, Scintimun®, is also approved in 32 European countries and Mexico. This expansion in product approvals signifies a strengthening of Telix’s market position in the medical imaging industry, potentially leading to increased revenue and a stronger competitive stance in the biopharmaceutical sector.
Telix Pharmaceuticals reported a record financial performance for FY2024 with a 56% increase in total revenue, driven primarily by sales of Illuccix®. The company achieved significant milestones, including expanding its global supply chain and preparing for new product launches in 2025. Telix’s strategic investments and acquisitions have positioned it for substantial growth in FY2025, with projected revenue guidance of up to $1.23 billion. The company’s focus on precision medicine, late-stage therapeutic development, and global delivery infrastructure expansion underscores its commitment to enhancing international market presence and patient access.
Telix Pharmaceuticals Ltd. announced its financial results for the fiscal year ending December 31, 2024, showcasing significant growth with a 56% increase in revenue, reaching AUD 783,207,000, and an 858% surge in profit after tax to AUD 49,919,000. This strong financial performance highlights Telix’s successful market positioning and operational efficiency, although no dividends were declared for the year.
Telix Pharmaceuticals announced that its prostate cancer imaging agent, Illuccix, has been approved by the UK Medicines and Healthcare Products Regulatory Agency. This approval addresses the growing demand and supply shortages of PSMA-PET imaging in the UK, which is a crucial development for prostate cancer management, offering improved accuracy over traditional imaging methods. The approval is expected to enhance Telix’s market position by improving access to prostate cancer diagnostics in the UK and potentially increasing its stakeholder value.
Telix Pharmaceuticals has announced the release of its full year results for the period ending December 31, 2024, scheduled for February 20, 2025. An investor webcast and conference call will take place the following day to discuss these results. This announcement is an important opportunity for stakeholders to gain insights into Telix’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.